Antimicrobial resistance (AMR) management using CRISPR-Cas based genome editing
Gene and Genome Editing, ISSN: 2666-3880, Vol: 7, Page: 100031
2024
- 1Citations
- 51Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations1
- Citation Indexes1
- CrossRef1
- Captures51
- Readers51
- 51
Review Description
Antimicrobial resistance is a serious threat to the human population and might be responsible for the emergence as well as re-emergence of various infectious diseases. The staggard development of new antibiotics and the resistance acquired by the pathogens against the existing antibiotics is indeed a menace and has aggravated due to the ongoing pandemic. CRISPR-Cas systems, an inherent immune mechanism present in prokaryotes is one of the most popular tools that was first harnessed in 2014 for selective removal of genes responsible for antimicrobial resistance. Gradually gaining considerable momentum in the field of genetics, medicine, and biotechnology, CRISPR-Cas technologies have been rapidly utilized in gene editing in human cells, designing animal models for disease progression studies to develop insect-resistant crop varieties and repurpose inherent bacterial CRISPR-Cas systems for target specific elimination of pathogens. The main aim of this review is to discuss how the CRISPR-Cas systems have been utilized to produce new-generation antimicrobials, associated delivery vehicles and challenges, and the prospects of these powerful antimicrobials.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know